An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.

摘要: Introduction: The era of molecular-targeted agents, particularly bevacizumab and cetuximab, has revolutionized the treatment paradigm for metastatic colorectal cancer (mCRC). Amongst multikinase inhibitors (MKIs) examined, regorafenib was first to establish its role in mCRC. Despite modest efficacy, this finding had reignited interest exploring MKIs with hope maximizing their therapeutic potential mCRC.Areas covered: This review summarizes previous studies mCRC, targeting two signaling pathways activated through vascular endothelial growth factor receptors epidermal receptors. article provides discussion a focus on: challenges encountered when combining MKI chemotherapy, lack predictive markers, strategies utilized address escape other targeted agents.Expert opinion: Clinical progress using mCRC been disappointing due limited efficacy. exact regora...